Abstract: The present invention provides type C crystal of compound I, type B crystal of compound II, or type C crystal of compound III set forth in this specification.

Abstract: Disclosed is a production method of a two-component developer for developing an electrostatic image comprising a toner and a resin coated carrier having a porous magnetic core particle and a resin coated layer, wherein the porous magnetic core particle are composed of a porous ferrite material and have pore apertures on a surface of the particle, and the method comprises steps of blocking the pore apertures of the porous magnetic core particle with rubber particles by dry mixing of the porous magnetic core particle and the rubber particles, forming the resin coated carrier by forming a resin layer on the porous magnetic core particle whose pore apertures have been blocked, and mixing the resin coated carrier and the toner.

Abstract: The present invention provides type C crystal of compound I, type B crystal of compound II, or type C crystal of compound III set forth in this specification.

Abstract: Disclosed is a production method of a two-component developer for developing an electrostatic image comprising a toner and a resin coated carrier having a porous magnetic core particle and a resin coated layer, wherein the porous magnetic core particle are composed of a porous ferrite material and have pit apertures on a surface of the particle, and the method comprises steps of blocking the pit apertures of the porous magnetic core particle with rubber particles by dry mixing of the porous magnetic core particle and the rubber particles, forming the resin coated carrier by forming a resin layer on the porous magnetic core particle whose pore openings have been blocked, and mixing the resin coated carrier and the toner.

Abstract: The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so on Wherein all symbols in formula are as defined in the specification.

Abstract: The compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof specifically binds CCR5, so it is useful for preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection diabetes cancer metastasis and so on.